0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover315.76%IV-190.14%PremiumMay 16, 2025Expiry Date9.83Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8415Delta0.0623Gamma0.51Leverage Ratio-0.0208Theta-0.0059Rho-0.43Eff Leverage0.0031Vega
Pulmonx Stock Discussion
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System...
No comment yet